靶向治疗联合放化疗治疗肺癌脑转移患者的临床疗效分析

Analysis of clinical effect by targeted therapy combined with chemoradiotherapy in the treatment of lung cancer with brain metastasis patients

目的分析靶向治疗联合放化疗治疗肺癌脑转移患者的临床疗效。方法 90例肺癌脑转移患者,随机分成对照组和观察组,各45例。对照组采用全脑放化疗同步治疗,观察组在对照组的基础上联合靶向药物治疗。比较两组疗效。结果观察组治疗总有效率为95.56%,明显高于对照组的44.44%(P<0.01)。观察组治疗后皮疹、肝功损害、脱发、消化道反应、骨髓抑制的不良反应发生率(2.22%、6.67%、8.89%、4.44%、4.44%)均低于对照组(13.33%、22.22%、24.44%、17.78%、20.00%)(P<0.05)。结论靶向治疗联合放化疗治疗肺癌脑转移患者的临床疗效显著,能明显改善患者的生活质量,且不良反应发生率低,安全性高,值得临床推广应用。

Objective To analyze clinical effect by targeted therapy combined with chemoradiotherapy in the treatment of lung cancer with brain metastasis patients. Methods A total of 90 lung cancer with brain metastasis patients were randomly divided into control group and observation group, with 45 cases in each group. The control group received whole brain chemoradiotherapy concomitant therapy, and the observation group received additional combination of targeted therapy. Curative effects were compared between the two groups. Results The observation group had higher total effective rate as 95.56% than 44.44% in the control group （P〈0.01）. The observation group had all lower incidence of rash, liver functional impairment, alopecia, gastrointestinal reaction and myelosuppression as adverse reactions （2.22%, 6.67%, 8.89%, 4.44% and 4.44%） than the control group （13.33%, 22.22%, 24.44%, 17.78% and 20.00%） （P〈0.05）. Conclusion Combination of targeted therapy and chemoradiotherapy shows precisely clinical effect in treating lung cancer with brain metastasis patients. This method can remarkably improve quality of life in patients, along with low incidence of adverse reactions and high safety. It is worth clinical promoting and applying.